The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative drugs? It’s simple to explain as the market place doesn’t work for drugs for quite serious reasons. Primarily, the end-user…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain to our readers the main differences between this organization in France and the US FDA? AFSSAPS was created in 1999…
Boasting three Nobel Prize winners from the life sciences, Argentina has had a long history of innovation. Immigration from Europe at the end of the 19th century saw the genesis of many of the national pharmaceutical companies that today control over 53% of the market. Access to highly qualified…
France What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that we can no longer live during this crisis without letting people express themselves genuinely. And I don’t mean expression of…
Paion Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company we see today? The reason for founding Paion in 2000 was more a question of timing of our own development.…
Hikma Pharma One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the Hikma organisation, and how important are Hikma’s German operations for the company today? Hikma first established operations in Germany in…
Cytolon You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to achieve your mission of making Cytolon AG the world’s first source of cord blood? Cytolon was the result of a…
Biomax Informatics Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company and how successful have you been so far in achieving your aims? When I founded the company 10 years ago,…
GlaxoSmithKline Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these evolved since you stepped into that role in April 2010? The ABPI represents the R&D and innovation-based pharmaceutical companies in…
IMS Health Germany Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been the partner of the pharmaceutical industry for over fifty years and has evolved alongside it. IMS today is the partner…
BioSino Bio-Technology & Science Inc BioSino has experienced many changes since it was first established and has taken on many different forms and functions. Can you provide a brief history of the company and the current structure of the company? I would say there are four phases to BioSino’s history. The roots of the company…
Poen ¿Cuál es la historia de Laboratorios Poen y como ha crecido en los últimos años? Poen se inició siendo un pequeño laboratorio de capitales nacionales dedicado fundamentalmente a la oftalmología. Hoy somos el único laboratorio de la Argentina con una planta que elabora exclusivamente productos oftálmicos y estamos ya cerca…
See our Cookie Privacy Policy Here
